BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial; Secondary endpoint of non-inferiority achieved for the risk of composite of M

Media coverage

• Title	BRILINTA Monotherapy in High-Bleeding Risk Patients Who Underwent PCI had Reduced Risk of Clinically Relevant Bleeding Than With Dual Antiplatelet Therapy in the TWILIGHT Trial; Secondary endpoint of non-inferiority achieved for the risk of composite of M
  Media name/outlet	Business Wire
  Country/Territory	United States
  Date	26/09/19
  Persons	Roxana Mehran,